ALSO NOTED: Novartis, Schering-Plough to collaborate; China confirms new bird flu death;and much more...

> Novartis and Schering-Plough announced they will collaborate on a new, once-daily therapy for asthma. The new treatment will combined Schering-Plough's  Asmanex asthma drug with Novartis' medication indacaterol. Report

> China has confirmed its fourteenth death from the lethal H5N1 virus. The list also includes the first death from bird flu in 2003, which the country acknowledged only last week. Report

> GlaxoSmithKline and Shionogi have completed their first clinical trial of an experimental AIDS/HIV therapy that belongs to a new class of integrase inhibitors. Report

> MedImmune has responded to the FDA's request for more information regarding a new version of its flu vaccine that will only need to be stored in a refrigerator rather than a freezer. Report

> Savient Pharmaceuticals is buying back 10 million of its shares. Report

> China's Aida Pharmaceuticals, which is working in the field of gene therapy, has completed the acquisition of Shanghai Qiaer Bio-Technology. Release

And Finally… A federal advisory panel has suggested easing rules that have long prohibited researchers from using prisoners in drug trials. Article

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.